Literature DB >> 7149824

Comparative influence of blood-borne nonbacterial particles and Staphylococcus aureus on fibronectin, complement and immunoglobulin.

M H McCafferty, T M Saba.   

Abstract

Opsonic fibronectin deficiency has been documented in septic injured patients and suspected to reflect acute depletion due to blood-borne nonbacterial particulates. In the present study, the comparative effect of intravenous infusion of heat-killed Staphylococcus aureus or gelatin-coated nonbacterial test particles on immunoreactive fibronectin, IgG and C3 was investigated. These two test particles were selected because of their known dependence upon adequate opsonization for efficient RES phagocytic removal. The intravenous injection of gelatin-coated RE test lipid emulsion (50 mg/100 gm body weight) resulted in an acute depletion of serum fibronectin with no major alteration in circulating IgG or C3. This selective depletion of fibronectin was followed by a rapid restoration and elevation of fibronectin level within 24 hours. In contrast, intravenous infusion of heat-killed S. aureus (1 X 10 11/rat) resulted in an acute depletion of fibronectin and C2 within 60 minutes. The deficiency of these opsonic proteins after bacterial challenge was followed by elevation of fibronectin and normalization of C2. IgG was not significantly changed at any time. The decline in fibronectin and C3 was greater with an increase in bacterial dose. These studies emphasize the specificity of the opsonic deficiency induced by gelatin-coated particles. Additionally, the suggest that opsonic deficiency with S. aureus bacteremia may be, in part, functionally related to disturbances of fibronectin. The role of fibronectin deficiency in documented states of opsonic deficiency with sepsis warrants consideration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149824      PMCID: PMC1352991          DOI: 10.1097/00000658-198212001-00018

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Binding of soluble form of fibroblast surface protein, fibronectin, to collagen.

Authors:  E Engvall; E Ruoslahti
Journal:  Int J Cancer       Date:  1977-07-15       Impact factor: 7.396

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Reticuloendothelial blockade and recovery as a function of opsonic activity.

Authors:  T M Saba; N R Di Luzio
Journal:  Am J Physiol       Date:  1969-01

4.  Electroimmunoassay of alpha-2-opsonic protein during reticuloendothelial blockade.

Authors:  F Blumenstock; P Weber; T M Saba; R Laffin
Journal:  Am J Physiol       Date:  1977-03

5.  Fibronectin binds to Staphylococcus aureus.

Authors:  P Kuusela
Journal:  Nature       Date:  1978-12-14       Impact factor: 49.962

6.  Biochemical and immunological characterization of human opsonic alpha2SB glycoprotein: its identity with cold-insoluble globulin.

Authors:  F A Blumenstock; T M Saba; P Weber; R Laffin
Journal:  J Biol Chem       Date:  1978-06-25       Impact factor: 5.157

7.  Consumptive opsoninopathy: possible pathogenesis in lethal and opportunistic infections.

Authors:  J W Alexander; M A McClellan; C K Ogle; J D Ogle
Journal:  Ann Surg       Date:  1976-12       Impact factor: 12.969

8.  Opsonic alpha2 surface binding glycoprotein therapy during sepsis.

Authors:  W A Scovill; T M Saba; F A Blumenstock; H Bernard; S R Powers
Journal:  Ann Surg       Date:  1978-10       Impact factor: 12.969

9.  Cryoprecipitate reversal of opsonic alpha2-surface binding glycoprotein deficiency in septic surgical and trauma patients.

Authors:  T M Saba; F A Blumenstock; W A Scovill; H Bernard
Journal:  Science       Date:  1978-08-18       Impact factor: 47.728

10.  Cardiovascular hemodynamics after opsonic alpha-2-surface binding glycoprotein therapy in injured patients.

Authors:  W A Scovill; S J Annest; T M Saba; F A Blumenstock; J C Newell; H H Stratton; S R Powers
Journal:  Surgery       Date:  1979-08       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.